Company Profile
Alkermes plc Stock Price, News & Analysis
- Ticker:
- ALKS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Ireland
Stock performance
52.73 USD (-0.30%)
Close
Last updated: July 27, 2026
6.89B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, ALKS closed down 0.30% at $52.73. No new same-company headline was identified in the current news window.
Company overview
Business overview
Alkermes is a biopharmaceutical company focused on neuroscience, addiction medicine, and specialty therapeutics. Its portfolio combines commercial products and development programs across CNS and related areas.
Geographic Base and Sector Classification
Alkermes is headquartered in Ireland and listed on NASDAQ. It has a global footprint with a strong U.S. commercial base.
Business Model Characteristics
The company generates value through product sales, neuroscience development, and lifecycle management across a specialty portfolio. Investors watch commercial execution, pipeline progress, and strategic allocation.
Position Within the Biotechnology Landscape
Alkermes sits in the upper tier of specialty neuroscience biotech. It is more durable than a pure development-stage name, but catalyst events still matter to the story.
Future catalysts
Alkermes’ catalysts are VIVITROL, Lybalvi, and any CNS pipeline update that broadens the company’s growth mix. Investors will watch whether the commercial base stays durable.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
BCLI · Source: Brainstorm Cell Therapeutics Inc.
- 02
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
DNLI · Source: Denali Therapeutics
- 03
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
TNXP · Source: Tonix Pharmaceuticals
- 04
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
IKT · Source: Inhibikase Therapeutics
- 05
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
KTTA · Source: Pasithea Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Alkermes plc (ALKS)?
Alkermes plc (ALKS) most recently closed at 52.73 USD, a -0.30% move versus the previous session.
What is the market cap of Alkermes plc (ALKS)?
Alkermes plc currently has a market capitalization of 6.89B USD on BioPharmSignal.
What does Alkermes plc do?
Alkermes is a biopharmaceutical company focused on neuroscience, addiction medicine, and specialty therapeutics. Its portfolio combines commercial products and development programs across CNS and related areas.
On which exchange is ALKS stock listed?
Alkermes plc (ALKS) is associated with NASDAQ, Ireland, Biopharma.
What is Alkermes?
Alkermes’ catalysts are VIVITROL, Lybalvi, and any CNS pipeline update that broadens the company’s growth mix.
Which conditions is Alkermes plc targeting with Alkermes?
Alkermes plc is associated with neuroscience based on its company overview and current catalyst commentary.
How does Alkermes plc describe recent progress with Alkermes?
Alkermes’ catalysts are VIVITROL, Lybalvi, and any CNS pipeline update that broadens the company’s growth mix.
What is Lybalvi?
Alkermes’ catalysts are VIVITROL, Lybalvi, and any CNS pipeline update that broadens the company’s growth mix.